Literature DB >> 12846572

Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers.

Melissa Smellie1, Deravander S Bose, Andrew S Thompson, Terence C Jenkins, John A Hartley, David E Thurston.   

Abstract

Members of a homologous series of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers with C8-O-(CH(2))(n)-O-C8' diether linkages (n = 3-6 for 2a-d, respectively) have been studied for their ability to interact with oligonucleotide duplexes containing potential target binding sites. The results confirm earlier predictions that the n = 3 analogue (2a, DSB-120) will covalently bind to a 5'-Pu-GATC-Py sequence by cross-linking opposite-strand guanines separated by 2 bp. Preference for this DNA sequence is shown using oligonucleotides with altered bases between and/or flanking these guanines. The more extended PBD dimer 2c (n = 5) can span an extra base pair and cross-link the 5'-Pu-GA(T/A)TC-Py sequence. The ability of each homologue to cross-link linear plasmid DNA has been determined, with a rank order that correlates with the reported order of in vitro cytotoxicity: n = 3 (2a) > n = 5 (2c) > n = 6 (2d) > n = 4 (2b). The n = 3 homologue (2a) is >300-fold more efficient at cross-linking DNA than the clinically used cross-linking agent melphalan under the same conditions. Kinetic studies reveal that the n = 3 and 5 dimers achieve faster cross-linking to plasmid DNA (108 and 81% cross-linking h(-1) microM(-1) at 37 degrees C, respectively), whereas the n = 4 and 6 homologues are significantly less efficient at 10.3 and 23% cross-linking h(-1) microM(-1), respectively. Alternating activity for the odd n and even n dimers is probably due to configurational factors governed by the spatial separation of the PBD subunits and the flexible character of the tethering linkage. Molecular modeling confirms the order of cross-linking reactivity, and highlights the role of linker length in dictating sequence recognition for this class of DNA-reactive agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846572     DOI: 10.1021/bi034313t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

Review 1.  Emerging therapies for acute myeloid leukemia: translating biology into the clinic.

Authors:  Simon Kavanagh; Tracy Murphy; Arjun Law; Dana Yehudai; Jenny M Ho; Steve Chan; Aaron D Schimmer
Journal:  JCI Insight       Date:  2017-09-21

2.  Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.

Authors:  Jason B White; Ryan Fleming; Luke Masterson; Ben T Ruddle; Haihong Zhong; Christine Fazenbaker; Patrick Strout; Kim Rosenthal; Molly Reed; Vanessa Muniz-Medina; Philip Howard; Rakesh Dixit; Herren Wu; Mary Jane Hinrichs; Changshou Gao; Nazzareno Dimasi
Journal:  MAbs       Date:  2019-03-05       Impact factor: 5.857

3.  SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

Authors:  John A Hartley; Anzu Hamaguchi; Marissa Coffils; Christopher R H Martin; Marie Suggitt; Zhizhi Chen; Stephen J Gregson; Luke A Masterson; Arnaud C Tiberghien; Janet M Hartley; Christopher Pepper; Thet Thet Lin; Christopher Fegan; David E Thurston; Philip W Howard
Journal:  Cancer Res       Date:  2010-07-26       Impact factor: 12.701

4.  Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

Authors:  Maureen C Ryan; Maria Corinna Palanca-Wessels; Brian Schimpf; Kristine A Gordon; Heather Kostner; Brad Meyer; Changpu Yu; Heather A Van Epps; Dennis Benjamin
Journal:  Blood       Date:  2017-09-13       Impact factor: 22.113

5.  Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.

Authors:  Gary P Wilkinson; James P Taylor; Steve Shnyder; Patricia Cooper; Phil W Howard; David E Thurston; Terence C Jenkins; Paul M Loadman
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

6.  Biosynthesis, Mechanism of Action, and Inhibition of the Enterotoxin Tilimycin Produced by the Opportunistic Pathogen Klebsiella oxytoca.

Authors:  Evan M Alexander; Dale F Kreitler; Valeria Guidolin; Alexander K Hurben; Eric Drake; Peter W Villalta; Silvia Balbo; Andrew M Gulick; Courtney C Aldrich
Journal:  ACS Infect Dis       Date:  2020-06-24       Impact factor: 5.084

7.  Response of Staphylococcus aureus to subinhibitory concentrations of a sequence-selective, DNA minor groove cross-linking pyrrolobenzodiazepine dimer.

Authors:  Marie Doyle; Eva-Anne Feuerbaum; Keith R Fox; Jason Hinds; David E Thurston; Peter W Taylor
Journal:  J Antimicrob Chemother       Date:  2009-09-10       Impact factor: 5.790

8.  DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057.

Authors:  John A Hartley; Anzu Hamaguchi; Marie Suggitt; Stephen J Gregson; David E Thurston; Philip W Howard
Journal:  Invest New Drugs       Date:  2011-03-08       Impact factor: 3.850

9.  Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers.

Authors:  Khondaker M Rahman; Colin H James; David E Thurston
Journal:  Nucleic Acids Res       Date:  2011-03-21       Impact factor: 16.971

10.  Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates.

Authors:  Khondaker M Rahman; Helena Rosado; Joao B Moreira; Eva-Anne Feuerbaum; Keith R Fox; Eva Stecher; Philip W Howard; Stephen J Gregson; Colin H James; Maria de la Fuente; Denise E Waldron; David E Thurston; Peter W Taylor
Journal:  J Antimicrob Chemother       Date:  2012-04-30       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.